These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 34416319)

  • 41. Single-cell sequencing of PBMC characterizes the altered transcriptomic landscape of classical monocytes in BNT162b2-induced myocarditis.
    Hwang N; Huh Y; Bu S; Seo KJ; Kwon SH; Kim JW; Yoon BK; Ahn HS; Fang S
    Front Immunol; 2022; 13():979188. PubMed ID: 36225942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study.
    Kildegaard H; Lund LC; Højlund M; Stensballe LG; Pottegård A
    BMJ; 2022 Apr; 377():e068898. PubMed ID: 35410884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination.
    Aydoğan Bİ; Ünlütürk U; Cesur M
    Endocrine; 2022 Oct; 78(1):42-46. PubMed ID: 35809159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination.
    Kim SH; Lee SY; Kim GY; Oh JS; Kim J; Chun KJ; Ju MH; Lee CH; Song YJ; Na JY
    J Korean Med Sci; 2022 Apr; 37(13):e104. PubMed ID: 35380028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction.
    Ameratunga R; Woon ST; Sheppard MN; Garland J; Ondruschka B; Wong CX; Stewart RAH; Tatley M; Stables SR; Tse RD
    J Clin Immunol; 2022 Apr; 42(3):441-447. PubMed ID: 34978002
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
    Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A
    BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine.
    Leone MC; Canovi S; Pilia A; Casali A; Depietri L; Fasano T; Colla R; Ghirarduzzi A
    Thromb Res; 2022 Mar; 211():60-62. PubMed ID: 35081484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults.
    Simone A; Herald J; Chen A; Nayak R; Shen YA; Lee MS
    Int J Cardiol; 2022 Oct; 365():41-43. PubMed ID: 35870635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
    Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
    Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An autopsy case of fulminant myocarditis after severe acute respiratory syndrome coronavirus 2 vaccine inoculation.
    Satomi H; Katano H; Kanno H; Kobayashi M; Ohkuma Y; Hashidume N; Usui T; Tsukada S; Ito I
    Pathol Int; 2022 Oct; 72(10):519-524. PubMed ID: 36040128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparing the B and T cell-mediated immune responses in patients with type 2 diabetes receiving mRNA or inactivated COVID-19 vaccines.
    Lee CH; Gray V; Teo JMN; Tam AR; Fong CH; Lui DT; Pang P; Chan KH; Hung IF; Tan KC; Ling GS
    Front Immunol; 2022; 13():1018393. PubMed ID: 36304475
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
    Heshin-Bekenstein M; Ziv A; Toplak N; Hagin D; Kadishevich D; Butbul YA; Saiag E; Kaufman A; Shefer G; Sharon O; Pel S; Elkayam O; Uziel Y
    Rheumatology (Oxford); 2022 Nov; 61(11):4263-4272. PubMed ID: 35179569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines.
    Naveed Z; Li J; Wilton J; Spencer M; Naus M; Velásquez García HA; Kwong JC; Rose C; Otterstatter M; Janjua NZ;
    J Am Coll Cardiol; 2022 Nov; 80(20):1900-1908. PubMed ID: 36357091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
    Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.
    Zambrano LD; Newhams MM; Olson SM; Halasa NB; Price AM; Boom JA; Sahni LC; Kamidani S; Tarquinio KM; Maddux AB; Heidemann SM; Bhumbra SS; Bline KE; Nofziger RA; Hobbs CV; Bradford TT; Cvijanovich NZ; Irby K; Mack EH; Cullimore ML; Pannaraj PS; Kong M; Walker TC; Gertz SJ; Michelson KN; Cameron MA; Chiotos K; Maamari M; Schuster JE; Orzel AO; Patel MM; Campbell AP; Randolph AG;
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(2):52-58. PubMed ID: 35025852
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2.
    Dickey JB; Albert E; Badr M; Laraja KM; Sena LM; Gerson DS; Saucedo JE; Qureshi W; Aurigemma GP
    JACC Cardiovasc Imaging; 2021 Sep; 14(9):1862-1863. PubMed ID: 34246585
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
    Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
    PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19.
    Bautista García J; Peña Ortega P; Bonilla Fernández JA; Cárdenes León A; Ramírez Burgos L; Caballero Dorta E
    Rev Esp Cardiol (Engl Ed); 2021 Sep; 74(9):812-814. PubMed ID: 33994339
    [No Abstract]   [Full Text] [Related]  

  • 60. Myocarditis following COVID-19 vaccination in adolescents and adults: a cumulative experience of 2021.
    Ilonze OJ; Guglin ME
    Heart Fail Rev; 2022 Nov; 27(6):2033-2043. PubMed ID: 35449353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.